Wednesday, March 29, 2023


Biotechnology News Magazine

DocSun Biomedical Limited Completes Technology Transfer to Future Now Biotech LLC

Latest Posts

Risk From Pharma Reps Using Unapproved Content and Messaging in the Field Persists, but a Focus on Training Could Be the Answer

ACTO advises Study Reveals 50% of respondents in leadership roles catch incidents of field reps using unapproved content, but a continuous learning culture could eliminate this behavior.

Entrinsic Bioscience® Expands enterade® Brand with Innovative Approach to the Dietary Support of Irritable Bowel Syndrome with Diarrhea (IBS-D

enterade® IBS-D is the first medical food formulated with plant-based amino acids and electrolytes for Irritable Bowel Syndrome with Diarrhea (IBS-D)-

Russell Finex Helps Leading Pharmaceutical Company Meet High Levels Of Demand With The Russell Compact Sieve

To ensure the highest quality final product, the company reached out to Russell Finex for a high-capacity vibrating screen. After assessing the company’s requirements, Russell Finex recommended the Russell Compact Sieve® as the ideal solution for check-screening pharmaceutical powders due to its stainless-steel contact parts, and easy-to-clean strip down design.

How Biotech Businesses Can Benefit from Freelance Experts

Ashmita Das, CEO of open talent platform Kolabtree, shares some of Kolabtree freelancer’s success stories.

DocSun Biomedical Limited (“DocSun“) a leading medical research firm, today announced the completion of technology transfer to Future Now Biotech LLC (“Future Now”), a rapid growing biotech company. The transfer includes a wide range of proprietary technologies and intellectual property, including cutting-edge medical research and innovative medical devices.

“We are thrilled to be transferring our tech and IPs to Future Now,” said Mike Chen, CEO of DocSun Biomedical. “Our two companies share a common goal of improving healthcare and advancing medical technology, and this transfer will allow us to continue our mission on a larger scale.”

The transfer of technology and IP will enhance Future Now’s ability to bring innovative medical solutions to market faster, providing patients with the latest in cutting-edge medical technology. The company is committed to use DocSun technology to help advance medical research and improve patient outcomes.

“The acquisition of DocSun’s technologies and IPs is a significant step forward for Future Now,” said Gary Kiss, CEO of Future Now.  “We look forward to leveraging these resources to help drive our growth and continue our mission of advancing medical technology for the betterment of human health.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine